Quick Answer
Resistant Starch Gut Microbiome Meta-Analysis has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3 The condition now referred to as metabolic dysfunction-associated fatty liver disease has traversed a long and contested nosological path.
Key Takeaways
- 011 2 3 The condition now referred to as metabolic dysfunction-associated fatty liver disease has traversed a long and contested nosological path. [Wang Rui (2026)]
- 02Throughout this review, we use the term MASLD (metabolic dysfunction-associated steatotic liver disease) as the current preferred nomenclature, while retaining the historical terms NAFLD and MAFLD when describing the evolution of the field or citing studies that employed those frameworks. [Wang Rui (2026)]
- 03When Ludwig, Viggiano, McGill, and Oh introduced “non-alcoholic steatohepatitis” (NASH) in 1980, they described hepatic macrovesicular steatosis with lobular inflammation in patients whose alcohol consumption fell well below the threshold typically associated with alcoholic liver injury (). [Wang Rui (2026)]
- 04Over four decades, what began as a histological description has evolved into one of the most extensively studied metabolic conditions of the 21st century, driven by the parallel global rise in obesity, type 2 diabetes, and sedentary lifestyles. [Wang Rui (2026)]
The current Migaku evidence database contains 2 reusable source documents for Resistant Starch Gut Microbiome Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove.
- 1 2 3 The condition now referred to as metabolic dysfunction-associated fatty liver disease has traversed a long and contested nosological path. [Wang Rui (2026); evidence level 3]
- Throughout this review, we use the term MASLD (metabolic dysfunction-associated steatotic liver disease) as the current preferred nomenclature, while retaining the historical terms NAFLD and MAFLD when describing the evolution of the field or citing studies that employed those frameworks. [Wang Rui (2026); evidence level 3]
- When Ludwig, Viggiano, McGill, and Oh introduced “non-alcoholic steatohepatitis” (NASH) in 1980, they described hepatic macrovesicular steatosis with lobular inflammation in patients whose alcohol consumption fell well below the threshold typically associated with alcoholic liver injury (). [Wang Rui (2026); evidence level 3]
- Over four decades, what began as a histological description has evolved into one of the most extensively studied metabolic conditions of the 21st century, driven by the parallel global rise in obesity, type 2 diabetes, and sedentary lifestyles. [Wang Rui (2026); evidence level 3]
- Reduced renal sodium excretion promotes salt and volume expansion, while sympathetic nervous system overactivity and activation of the renin–angiotensin–aldosterone system further increase vascular resistance, sodium retention, and blood pressure. [Agustin Maya (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources